MGMT and central nervous system cancer: Consistent with the results shown in CGGA-325 dataset, elevations of LOXs expressions were observed in the glioma patients with higher grade, older age or MGMT unmethylated status while the patients with IDH-mutation or 1p/19q co-deletion displayed the reductions of LOXs mRNA expressions (Figures 2H–N and Figures 3E–H in CGGA-693 and Supplementary Figures S2A–E and Supplementary Figures S3A–E in TCGA).